Ustekinumab for Hidradenitis Suppurativa: A Case Report

Santos-Pérez, M.I.; García-Rodicio, S.; Olmo-Revuelto, M.A. del; Pozo-Román, T

doi:10.1016/j.adengl.2014.06.003

Cited by 19 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…83 The patients in 6 additional case reports had variable responses. [84][85][86][87] It is possible that higher dosing similar to that used in inflammatory bowel disease would be more successful in HS, but no data currently exist.…”

Section: Il-12/il-23 Inhibitorsmentioning

confidence: 99%

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations

Alikhan

Sayed

Alavi

et al. 2019

Journal of the American Academy of Dermatology

301

556

View full text Add to dashboard Cite

show abstract

Section: Il-12/il-23 Inhibitorsmentioning

confidence: 99%

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations

Alikhan

Sayed

Alavi

et al. 2019

Journal of the American Academy of Dermatology

301

556

View full text Add to dashboard Cite

show abstract

“…To date, eight HS patients have been treated with 45 mg ustekinumab subcutaneously, mostly at weeks 0, 4, and 12, followed by every 3 months. Four patients showed a complete remission of their HS, three patients had a partial response, and one patient did not respond to ustekinumab treatment [82][83][84][85]. During the 23rd European Academy of Dermatology and Venereology (EADV) congress in 2014 in Amsterdam, Blok et al [86] presented the results of the first prospective open-label study of ustekinumab in HS patients.…”

Section: Ustekinumabmentioning

confidence: 99%

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Deckers

Prens

2015

Drugs

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease characterized by recurrent inflammatory nodules mostly located in the armpits and groin. Over the years multiple treatments for HS have been proposed; however, to date a cure is still lacking. In this update we provide an overview of most drug treatments reported on for HS, where possible with their mode of action and side effects. In mild cases, clindamycin lotion or resorcinol cream have proven effective. Tetracyclines are a first-line systemic option in more widespread or severe cases, followed by the combination of clindamycin and rifampicin. However, the recurrence rate is high after discontinuation of clindamycin plus rifampicin combination therapy. Long-term treatment with retinoids, especially acitretin is feasible, although teratogenicity has to be taken into account in females of reproductive age. Multiple antiinflammatory drugs have been suggested for HS, such as dapsone, fumarates or cyclosporine. However, their effectiveness in HS is based on small case series with varying results. If most common treatments have failed, biologics (e.g., infliximab or adalimumab) are the next step. Although not addressed in this review, surgical interventions are often needed to achieve remission. Key PointsHidradenitis suppurativa (HS) is a chronic inflammatory skin disease without a cure.Antibiotics (topical or oral) are often the first treatment option for HS.In cases of more extensive or therapy-resistant HS, biologicals (e.g., infliximab or adalimumab) are a good therapeutic option.

show abstract

“…Among them, we selected five articles describing UST treatment for HS. [5][6][7][8][9] We summarized information of study designs, age, sex and nationality of patients, conditions of HS and comorbidity, their previous biologic treatments, doses of UST, periods required to improve HS symptoms, treatment periods, and final outcomes from the five articles and our case ( Table 1). Four articles and our data are retrospective case note presentations.…”

Section: Case Reportmentioning

confidence: 99%

Ustekinumab treatment for hidradenitis suppurativa

Takeda

Kikuchi

Kanazawa

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

Hidradenitis suppurativa (HS) is a follicular occlusive inflammatory skin disease that occurs in the axilla, groin, buttocks and vulval region. Control of the intractable inflammation is a primary goal of HS treatments. Benefit of anti‐tumor necrosis factor (TNF) antibodies against HS have been reported, and adalimumab has been approved for HS in Europe, the USA and Japan. However, the alternative therapies for anti‐TNF antibodies have not been established yet. We experienced a case of HS which developed during the infliximab treatment for Crohn’s disease (CD) and was well managed by ustekinumab (UST). We reviewed the articles relating to ustekinumab treatments for HS. Twenty‐four HS patients, 16 women and eight men, have been treated with ustekinumab. The average age was 35.7 ± 10.8 years (mean ± SD). All were of Hurley stage II or III. Ten (10/24, 41.6%) had received anti‐TNF drugs including infliximab, adalimumab and etanercept prior to UST treatment for HS. Although the initial doses varied from 45 mg s.c. to 390 mg i.v., all cases were treated with 45 or 90 mg s.c. every 8 or 12 weeks at the regular dose, by following the regimen for psoriasis or CD. HS in most of the cases started to improve after 3–5 months of UST initiation, and some achieved complete remission. To our knowledge, our case is the first Asian HS patient improved by UST. Overall, UST is useful for HS and could be an alternative treatment if HS patients do not respond to other medications including anti‐TNF drugs.

show abstract

Ustekinumab for Hidradenitis Suppurativa: A Case Report

Cited by 19 publications

References 9 publications

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations

North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations

An Update on Medical Treatment Options for Hidradenitis Suppurativa

Ustekinumab treatment for hidradenitis suppurativa

Contact Info

Product

Resources

About